Goldman Sachs Ups STERIS 32.3% as Institutions Own 94.69%

For market participants parsing 13F season, STERIS plc offers a case study in institutional concentration risk and reward. Goldman Sachs's 32.3% quarterly position increase to $55 million — alongside Jane Street's 38.9% bump and Woodline's 40.0% add — shows smart money repositioning into the medical equipment name in the first half of 2026. But with 94.69% of shares locked up by institutions and director Richard Breeden trimming his stake 3.66% at $209.51, the trade is crowded enough that any earnings miss could amplify downside.

Stoneridge Investment Partners LLC initiated a new position in STERIS plc (NYSE: STE) during the second quarter of 2026, acquiring 4,497 shares valued at approximately $1.03 million, according to the firm's most recent SEC 13F disclosure. In isolation, a $1 million position is a modest allocation for an institutional investor, but the transaction lands within a broader pattern of accumulation by established institutional players that has pushed combined institutional ownership of the medical equipment provider to 94.69% of shares outstanding.

“

At Friday's $232.88 open on August 14, 2026, STE sat roughly 19% above its 52-week low of $195.14 and about 14% below its 52-week high of $269.44 — squarely in the middle of its annual range.

The most significant recent activity came in the first quarter of 2026. Goldman Sachs Group Inc. lifted its STERIS position by 32.3%, adding 59,264 shares to reach 242,732 shares valued at roughly $55 million. Jane Street Group LLC increased its holdings 38.9% to 20,716 shares worth about $4.7 million. Woodline Partners LP grew its stake 40.0% to 8,300 shares valued at $1.88 million. Jones Financial Companies LLP raised its position 46.1% to 1,106 shares. Empowered Funds LLC added 16.1% to reach 2,303 shares. These moves, confirmed across multiple filers, indicate that institutional demand for STERIS equity was not a one-off bet but a coordinated repositioning into the name across the first half of 2026.

That accumulation narrative is complicated — but not necessarily contradicted — by an insider transaction disclosed on June 2, 2026, when director Richard C. Breeden sold 1,481 shares at an average price of $209.51, generating $310,284.31. The sale reduced Breeden's direct stake by 3.66%, leaving him with 38,964 shares worth approximately $8.16 million. Insider sales are frequently interpreted as bearish signals, but a 3.66% trim at a price roughly 10% below the stock's August 14 opening level of $232.88 is more consistent with routine personal liquidity management or a pre-scheduled Rule 10b5-1 plan than a directional call on the company. The retained position of nearly 39,000 shares signals that Breeden remains materially exposed to STERIS's performance.

From a balance-sheet perspective, STERIS enters the second half of 2026 with a conservative capital structure: a debt-to-equity ratio of 0.23 and a quick ratio of 1.35. The low leverage gives the company flexibility to fund acquisitions or absorb pricing pressure, while the liquidity cushion supports operations through variable hospital capital-expenditure cycles. These metrics matter for a company whose end markets — infection prevention, sterilization services, and surgical consumables — are tied to hospital budgets and procedure volumes. STERIS's franchise benefits from regulatory moats and recurring, mission-critical consumables revenue, which helps explain why institutions have been willing to own such a large share of the float.